Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Brief Summary: The primary objective is to explore the efficacy and safety of an all oral combination of BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of previous chemotherapy and who for any reason are not suitable for further 'standard' intravenous chemotherapy treatments.


Options:
A: Arm Label: pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): placebo
B: Arm Label: Lead-in Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Extension - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: A. Non-Randomized Expansion (NRE) Cohort - Ovarian; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): A. Non-Randomized Expansion (NRE) Cohort - Ovarian, Lead-in Stage - cabozantinib (XL184), Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg, Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg, Open-Label Extension - cabozantinib (XL184), Randomized Stage - cabozantinib (XL184) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Stage - placebo
C: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
D: Arm Label: Arm I (cabozantinib-s-malate); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib S-malate, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel | Intervention Type: DRUG; Name: Cabozantinib S-malate; Assigned to Arm(s): Arm I (cabozantinib-s-malate) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (cabozantinib-s-malate), Arm II (paclitaxel) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm II (paclitaxel)

Answer: C